Category: SeaPRwire

Atlanta, Georgia – April 02, 2024 – (SeaPRwire) – In a world dominated by screens, where traditional learning methods often fall short, ColorPencil emerges as a beacon of hope. This innovative company is transforming the education landscape, particularly mathematics, by infusing creativity and playfulness into the learning experience. Gone are the days of dry textbooks and rote memorization. ColorPencil offers a refreshing approach, whisking children away on vibrant journeys through the enchanting world of Vedic math. Developed thousands of years ago in India, Vedic math provides a rich tapestry of ancient wisdom that empowers children of all learning styles to embrace numbers confidently and enthusiastically. Imagine a child who once found equations intimidating now confidently calculating angles using ancient counting rhymes. This isn’t a fantasy; it’s the reality for many young minds nurtured by ColorPencil. By tapping into natural patterns and mental shortcuts, Vedic math unlocks a more profound understanding, making complex calculations feel like a refreshing mental game rather than a daunting task. Moreover, ColorPencil recognizes and addresses the diverse needs of learners, including those with dyscalculia or ADHD. Their innovative products, such as GoColor and Fruitables, transcend traditional teaching methods by offering engaging tools that foster curiosity and understanding. Through vibrant visuals and interactive gameplay, children learn fundamental concepts and develop crucial skills such as communication and strategic thinking. Behind ColorPencil’s success are the visionary minds of Srinika, Srihari, Sriarvind, and their mother, Dharini. Their personal experiences with the transformative power of Vedic math inspired them to create something truly unique. Dharini aptly says, “We understand that traditional methods don’t work for everyone. That’s why we’ve created fun, engaging tools that break away from rote memorisation and spark a genuine love for numbers in children of all learning styles.” But ColorPencil’s mission extends beyond academic success. They are committed to social responsibility, aiming to uplift 1 million underprivileged children across Asia through education. Sustainable materials and eco-conscious practices positively impact both the environment and society. As ColorPencil embarks on its global adventure, its mission remains clear: to make learning a captivating journey for every child. In a world overrun by digital distractions, anxiety, and struggles with numbers, ColorPencil offers a refreshing oasis of creativity and playfulness. They are not just teachers of numbers but igniters of passion, transforming challenges into opportunities for growth, discovery, and lifelong success. Today, as their new website launches, we invite you to join the colourful revolution. Explore their innovative tools, discover their inspiring story, and connect with a community passionate about making learning an adventure. Witness the spark ignite in your child’s eyes as they embark on a journey of numbers, unlocking their full potential and paving the way for success in an ever-evolving world. Join the colourful revolution today! Visit ColorPencil’s website and unlock the magic of learning. Remember, even the most complex equations can be solved with a dash of creativity, a touch of playfulness, and a heart full of possibilities. Be the change. Empower the future—one colourful adventure at a time. Social Links Instagram: https://www.instagram.com/colorpencil.co/ LinkedIn: https://www.linkedin.com/company/colorpencil/ X: https://twitter.com/colorpencilco/ Facebook: https://www.facebook.com/eColorPencil?mibextid=LQQJ4d Media Contact Brand: ColorPencil Contact: Tudhgeet Kaur Website: https://www.colorpencil.com SOURCE: ColorPencil The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

New York, NY – 03/29/2024 – (SeaPRwire) – Today, BitGrid (https://BitGrid.cloud) is proud to announce the launch of their new solutions of intelligent quantitative trading. With the rapid development of the digital asset market and the constantly changing trading environment, investors’ demand for more efficient and intelligent trading methods is growing. However, traditional trading methods often face challenges such as information asymmetry, high transaction costs, and difficulties in risk control. It is in this context that BitGrid comes into play. BitGrid, as a company focused on intelligent financial technology, is committed to providing a new trading experience and value-added services for investors. The BitGrid AI Quantitative Strategy Profit Platform is a quantitative strategy profit platform driven by the large-scale model BitGrid GPT in quantitative finance. It is dedicated to integrating the latest artificial intelligence technology and quantitative financial strategies and supports various mainstream digital asset quantitative strategies. Utilizing professional quantitative tools to buy low and sell high in different exchanges, earning risk-free profits after the spread returns to normal. It also supports various fundamental quantitative strategies for digital assets. By leveraging advanced AI analysis capabilities, it continuously monitors and analyzes the complex dynamics of global financial markets, aiming to capture investment opportunities and achieve long-term stable growth. The BitGrid AI Quantitative Strategy Profit Platform represents the forefront of financial technology and provides investors with a unique and innovative asset management experience. Features of BitGrid’s AI-Trading System Intelligent Technology: Their platform combines artificial intelligence and big data analysis technology to achieve intelligent decision-making and automated trading, helping users easily obtain market profits. Security Guarantee: We adopt strict security measures and encryption technology to ensure the safety of users’ funds and data. Fully Automated Trading: Without the need for manual intervention by users, their trading system will automatically execute trading operations, ensuring the best trading timing and results. Continuous Optimization: Their team will continuously optimize and improve the platform’s trading algorithms and functionalities to enhance users’ trading experience and profitability. BitGrid’s future vision is to become the world’s leading intelligent quantitative trading platform, providing global investors with more intelligent and efficient trading solutions. We will continue to adhere to the spirit of innovation, continuously optimize and improve their products and services, and create greater value and returns for users. About BitGrid (https://BitGrid.cloud) BitGrid LLC is registered in Colorado, USA, and is a licensed AI quantitative strategy profit platform. Established in 2024, BitGrid is one of the forefront platforms using self-developed AI financial GPT models for hedging. It focuses on quantitative capital market research, quantitative investment, and risk management, with investment scope covering encrypted assets, stocks, futures, options, etc. The founding team consists of professors from the Wharton School of the University of Pennsylvania and financial PhDs, and the underlying strategy is based on their deep asset pricing theory and empirical research in behavioral finance. Media Contact Company: Bitgrid Financial Technology LLC Contact: Media team Website: https://BitGrid.cloud SOURCE: Bitgrid Financial Technology LLC The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

SHENZHEN, CHINA – 03/28/2024 – (SeaPRwire) – On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results. The Company recorded a turnover of RMB8,013 million, a year-on-year decrease of 12.4%; in the case that all medicines were directly sold by the Group, the turnover would be RMB 9,472 million, a year-on-year decrease of 9.8%. Profit for the year was RMB2,384 million, and normalized profit for the year that excluding provisions of impairment losses on related assets was RMB2,709 million. The results announcement shows that in 2023, the Company has affected by the implementation of the National Volume Based Procurement (the “National VBP”) of its three marketed original products (sales of these three products recorded a decrease of RMB1,708.7 million, and the sales of them for the second half of the year declined approximately 50% compared with the second half of last year), resulting in temporary turbulence and decline of its overall operation performance. Although three products have not been selected in the National VBP, they are all original medicines for chronic diseases with oral administration, with good brand recognition and large retail market shares. Therefore, the overall impact from National VBP could be expected. The Company’s exclusive non-VBP products has continued to grow. In addition, the Company’s newly marketed innovative product portfolio has been expanded to 4 drugs, and the commercialization and large-scale clinical application of innovative products has provided the Company fresh driving forces. Based on above, CMS has successfully entered into its “New Period” of innovation and internationalization development. 4 innovative drugs have started large-scale clinical application, unveiling CMS’s first year of commercialization era of innovative drugs. In 2023, CMS delivered quality innovation outcomes. Its three innovative drugs, Diazepam Nasal Spray (VALTOCO), Tildrakizumab Injection (ILUMETRI), Methotrexate Injection-psoriasis (METOJECT), have been included in the National Reimbursement Drug List (NRDL) after obtaining approvals of marketing in China, and have steadily entered into the commercialization stage, further enriching CMS’s marketed product matrix in the specialty therapeutical fields, and supporting CMS to accelerate commercialization process of innovative products. In addition, in February 2024, CMS obtained the exclusive license of the first-line phosphorus-lowering innovative drug Sucroferric Oxyhydroxide Chewable Tablets (VELPHORO), which has been newly included in the China NRDL and issued its first prescription in China. As of now, CMS’s 4 innovative drugs have officially started large-scale clinical application in China, marked as the start of the CMS’s commercialization era of innovative products The differentiated innovation pipeline stands as an important driver of the Company’s high-quality development. Driven by the twin-wheel of “Collaborative R&D and Independent R&D”, CMS has continuously deployed global first-in-class (FIC) and best-in-class (BIC) innovative products guided by patient and clinical demands, and has enhanced its R&D capabilities of differentiated innovative products to empower the continuous transformation of scientific research outcomes into clinical application. As of now, CMS has deployed approximately 30 innovative products. Among them, 2 products, Methotrexate Injection – rheumatoid arthritis (RA) and Methylthioninium Chloride Enteric-coated Sustained-release Tablets, are currently under NDA review in China. Meanwhile, over 10 innovative products are undergoing clinical trials in China, mainly randomized controlled trials (RCT). Furthermore, the Company has about 10 self-developed R&D innovation projects, covering large molecules, small molecules, siRNA, etc., among which Highly Selective TYK2 Inhibitor CMS-D001 tablets and GnRH Receptor Antagonist CMS-D002 capsules have obtained IND approvals in early 2024. CMS states that innovation products expected to be continuously launched every year with higher efficiency and more controllable costs starting from 2023, continuing to energize the Company’s mid- to long-term development. CMS is ready to embrace a brighter future full of opportunities. Rooted in specialty therapeutical fields, empowering products to achieve clinical and commercial values Commercialization capability is one of CMS’s core competitiveness. By continuously reinforcing and integrating its commercialization platform, the Company has further consolidated its specialty therapeutic fields focused operation system, and has promoted the independent operation of its three major business segments including cardio-cerebrovascular/gastroenterology, dermatology/medical aesthetics, and ophthalmology. Simultaneously, by leveraging upgraded compliance control system and supporting digital tools, CMS has continuously optimized its professional academic promotion capabilities guided by clinical evidence, and built a number of agile and efficient specialty therapeutical fields-focused commercialization teams. The Dermatology and Medical Aesthetic Business “CMS Skinhealth” regards dermatology prescription products as its core, and extends to dermatology-grade skincare products and light medical aesthetic products, continually optimizing full lifecycle skin-health management solutions. CMS Skinhealth has officially initiated the promotion of ILUMETRI, relying on the accumulated academic platform of existing marketed products including Hirudoid (the repair agent for skin barrier with multiple functions) and Aethoxysklerol (a German original brand for the treatment of sclerotherapy of varicose veins with years of clinical application). Meanwhile, CMS Skinhealth has obtained the exclusive licenses for the commercialization of three regenerative medical aesthetic products, including Poly-L-lactic Acid Microparticle Filler Injection, Polycaprolactone Microsphere Gel for Injection and Calcium Hydroxylapatite Microsphere Gel for Injection, enriching its regenerative medical aesthetic product portfolio and enhancing the Company’s competitiveness. The Ophthalmology Business “CMS Vision” continues to improve its organizational structure and operating system, and actively promotes the identification, development and commercialization of urgently needed clinical solutions. Innovative medical device, EyeOP1 Glaucoma Treatment Device, has completed market access in many provinces and cities, and is synergized with the exclusive marketed product Augentropfen Stulln Mono Eye Drops in marketing and promotion. VEGFA/ANG2 Tetravalent Bispecific Antibody, a class I innovative biological agent, is under the phase I clinical trial stage in China. The results announcement shows that as of the end of 2023, CMS has approximately 4,400 professional academic promotional personnel, and its promotion network has covered over 50,000 hospitals and medical institutions across China and nearly 250,000 retail pharmacies. CMS’s marketed products portfolio mainly includes exclusive branded drugs, with the successive approvals of innovative products in 2023, the Company’s future growth potential will be further released. At the same time, leveraging the accumulated advantages in cardio-cerebrovascular, gastroenterology, central nervous system, ophthalmology, dermatology and other specialty therapeutical fields, and its strong professional academic promotion capabilities, compliant and efficient management system, CMS has further enhanced its business efficiency and competitiveness to create broad commercial potential for its innovative products and exclusive products. Accelerating international business development, forging new growth engines Guided by the local unmet medical needs, CMS’s Southeast Asian business company “Rxilient Health”, leveraged the Group’s advantageous resource and operated by a local team with rich pharmaceutical industry expertise, has rapidly introduced a diverse product portfolio and established a business network covering various Southeast Asian countries. In March 2023, Rxilient Health entered into a collaboration agreement with Junshi Biosciences, leveraging Rxilient Health’s drug registration and commercialization advantages and Junshi Biosciences’s strong R&D strength, two parties to collaboratively develop and commercialize intravenous toripalimab, one of the key Chinese innovative drugs going overseas, in nine Southeast Asia countries. In December 2023, CMS and Rxilient Health joined hands with Pharmaron and others to jointly complete the acquisition of a manufacture plant in Singapore and accelerate the process of CDMO business. This cooperation is expected to improve the accessibility of quality drugs with unmet clinical needs in emerging markets and help global pharmaceutical companies to quickly enter markets such as Southeast Asia. The acquisition of Singapore manufacturing plant will optimize the CMS’s overseas supply chain and manufacturing capabilities, and enhance the stability of its international supply chain. Moreover, it will facilitate CMS to carry out product collaborations with its global partners in the future, continuously building a collaborative, mutually beneficial pharmaceutical innovation ecosystem. The Share Award Schemes enhances employee enthusiasm and creativity, enabling long-term binding towards a shared future for all. In order to maintain the momentum of innovation and accelerate the commercialization process of innovative products, on March 27, CMS announced the adoption of the “Share Award Scheme Related to CMS New Products”, which using the Company’s own funds to purchase its shares. No more than 100 million Shares will be granted to the Group’s core management and key personnel at nil consideration, subject to the satisfaction of certain performance targets and in compliance with the CMS Scheme to encourage them to continue to make outstanding contributions to the launch and sales of new products. According to the announcement, the schemes will determine “the stipulated performance targets” based on the overall financial performance of the Group, the cumulative sales revenue of a specified product or products, number of new products launched during any specified period. Among them, the “performance targets” associated with The First Batch of Share Awards include: launching 10 new products from 2020 to 2024. The cumulative total sales revenue of three blockbuster innovative drugs: METOJECT, VALTOCO, and VELPHORO in the three years from 2024 to 2026 will reach RMB2.5 billion. “Performance targets” associated with the future share awards include: the rolling share award scheme for the sales of new products, and to launch 12 new products from 2025 to 2027. In addition, the three independently operated business segments of “CMS Skinhealth”, “CMS Vision” and “Rxilient Health” will formulate the separate Share Award Schemes based on their respective business development situations. ILUMETRI, as a significant innovative product of “CMS Skinhealth”, will be included in the assessment under the separate Share Award Scheme of “CMS Skinhealth”. By continuously improving the long-term incentive mechanism, CMS closely links employee interests with the Company’s innovation development, maximizing employee enthusiasm to serve the Company’s long-term development diligently and responsibly. Furthermore, the schemes releases sufficient confidence to the capital market for the CMS’s steady development in the future. Looking ahead, CMS will embrace “New CMS and New Era” after the short period of turbulence. While accelerating its development under the guidance of innovation, CMS is firmly ushering in a new era. At the beginning of 2024, the term “innovative drugs” has been included in the government work report for the first time, indicating that innovative drugs have a leading strategic position among domestic emerging industries and have received great attention from the government. It will benefit pharmaceutical companies with advanced R&D capabilities, rich pipeline layouts, and mature commercialization systems. CMS is diligent and devoted to innovation, and has always adhered to its mission of providing competitive products and services to meet unmet medical needs. With the gradual digestion of national VBP implementation impacts on its existing products, and the further deepening of its innovation development, CMS has been well-prepared for a brighter future going forward and will return to the track of sustained and healthy growth. Under its compliant and efficient commercialization system, the Company’s innovative products and exclusive drugs will grow steadily. Concurrently, it is expected that more differentiated innovative products will be continuously launched with higher efficiency and more controllable costs every year in the future, continuously optimizing the Company’s marketed product structure. As a mature pharmaceutical company with excellent historical performance, although the turbulence of adjustment period is inevitable, with the continuous enhancement of its innovation strength, CMS will surely usher in a new cycle of performance growth. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Website: https://web.cms.net.cn/en/home/ Source: China Medical System Holdings Ltd. The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

Los Angeles, CA – 03/25/2024 – (SeaPRwire) – Lightkuo announces an exclusive collection of luxury home decor items, tailored for homeowners seeking elegance and style. Specializing in high-quality furnishings, lighting, and decorative accessories, Lightkuo aims to transform living spaces into sophisticated havens. With a focus on quality, uniqueness, and customer satisfaction, Lightkuo’s range caters to various tastes and room sizes, ensuring a personalized touch for every home. Discover the perfect decor to enhance users’ space’s appeal and reflect users’ individual style with Lightkuo’s expertly curated selection. For many years now, Lightkuo.com has been providing homeowners with high quality home decoration items that not only add appeal but also look to their space. Whatever decoration item the client is looking for, Lightkuo has it. This ranges from rugs, cups, lighting and other furnishings. To get the best result, the homeowner must have the knack for visualizing the best look for their home. Buyers should pay special attention to the home decor items that Lightkuo has to offer. By choosing these products wisely, users will not only be able to improve the looks of their homes but also have quality home decor items that will meet their preferences. With these products, the buyer will be able to accentuate the looks and style in their homes. High quality decor items Lightkuo understands that decor items can either make or break a homeowner’s space. They therefore ensure that their decorative elements look fresh and appealing so that they can enhance the appeal of a room. Lightkuo has quality décor items that will appeal to every taste and preferences. Experts at the store advise customers on a tight budget to start by purchasing a few of the quality decor items. This is because a room filled with a few classy and elegant decoration items will still look appealing. As a result, they focus on stocking products out of their magnificence rather than price. To get the best effect, users need to de-clutter their homes by removing the old stuff and replacing them with new décor items. For example, if a user has old metal décor in their home, they can remove them to give way for the new products. Therefore, it is wise to clear the pace as much as one can as this will leave space for new ideas. Fortunately, Lightkuo has a wide range of products for users to choose from. Whatever preferences a homeowner has when it comes to decor, they are assured of finding it at Lightkuo.com. Decor items that match with different home styles Lightkuo also stocks décor products that match well with different types of interiors. Therefore, the store has decor items that can match well with the existing furnishings, décor, and wall paint. Lightkuo professionals also understand that people have different sized rooms and houses. Therefore, they stock décor items of different sizes to suit these spaces. That way, buyers can purchase items of the right size without making a room look cluttered. Unique pieces Lightkuo has many unique pieces that can bring individuality to people’s homes. Items such as fashionable candle stands, artistic storage units, dior baccarat glasses, pottery, rugs, hand-crafted lamps and dior water bottle can improve the looks of a home. The key to making a home look unique lay in doing things different from other people. Instead of using the normal family portraits to decorate a wall, users can have royal mirrors, metalwork art, hang planters, or even bright placemats to make a wall look unique. About Lightkuo Lightkuo is a premiere home décor store that focuses on providing high-quality décor items to customers. Users can find a wide selection of products based on their needs and preferences. Media Contact Brand: Lightkuo Contact: Media team Website: https://www.lightkuo.com SOURCE: Lightkuo The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...